Showing 36,181 - 36,200 results of 227,974 for search '(( 5 ((ppm decrease) OR (mean decrease)) ) OR ( a ((point decrease) OR (a decrease)) ))', query time: 2.11s Refine Results
  1. 36181

    DataSheet_2_Monoallelic Heb/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia.xls by Diogo F. T. Veiga (12282320)

    Published 2022
    “…At the molecular level, HEB protein levels are decreased via proteasomal degradation at the leukemic stage, pointing to a reversible loss of function mechanism. …”
  2. 36182

    Image_5_Monoallelic Heb/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia.jpeg by Diogo F. T. Veiga (12282320)

    Published 2022
    “…At the molecular level, HEB protein levels are decreased via proteasomal degradation at the leukemic stage, pointing to a reversible loss of function mechanism. …”
  3. 36183

    Image_4_Monoallelic Heb/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia.jpeg by Diogo F. T. Veiga (12282320)

    Published 2022
    “…At the molecular level, HEB protein levels are decreased via proteasomal degradation at the leukemic stage, pointing to a reversible loss of function mechanism. …”
  4. 36184

    Table_1_Monoallelic Heb/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia.xls by Diogo F. T. Veiga (12282320)

    Published 2022
    “…At the molecular level, HEB protein levels are decreased via proteasomal degradation at the leukemic stage, pointing to a reversible loss of function mechanism. …”
  5. 36185

    Bioreductively Activatable Prodrug Conjugates of Combretastatin A‑1 and Combretastatin A‑4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia by Blake A. Winn (8604801)

    Published 2020
    “…The related CA1-<i>gem</i>-dimethylnitrothiophene BAPC <b>41</b> was also promising (HCR = 12.5) with complete cleavage (90 min) upon treatment with POR. In a preliminary in vivo dynamic bioluminescence imaging study, BAPC <b>45</b> (180 mg/kg, ip) induced a decrease (within 4 h) in light emission in a 4T1 syngeneic mouse breast tumor model, implying activation and vascular disruption.…”
  6. 36186

    Supplementary Material for: Alterations in Monocyte Phenotypes and Functions after a Hip Fracture in Elderly Individuals: A 6-Month Longitudinal Study by Baëhl S. (4159090)

    Published 2016
    “…An elevated expression of CX3CR1 was found only in iM. cM produced elevated quantities of TNFα. There was a transient oxidative burst of production before surgery in iM and a sustained decrease in ncM. …”
  7. 36187

    Illustration of controller breakdown of the scheme in Fig 2 when inflows to <i>A</i> exceed the outflows from <i>A</i>. by Peter Ruoff (248735)

    Published 2024
    “…<p>The setpoint of <<i>A</i>> is 2.0. Panel a: <i>A</i> (in black) and <<i>A</i>> (in blue) are shown as a function of time when <i>k</i><sub>1</sub> increases successively from <i>k</i><sub>1</sub>=1.0 (phase 1) to <i>k</i><sub>1</sub>=3.0 (phase 2), and finally to <i>k</i><sub>1</sub>=6.0 in phase 3. …”
  8. 36188

    (A-E) The lead compound can bind to mouse Dnmt3a (PDB: 4U7P ref [18]). by Vedran Miletić (3918584)

    Published 2017
    “…(<u><b>E</b></u>) The plots show changes in pulling force and the corresponding decrease in the number of dynamic binding interactions within Dnmt3a-inhibitor complex. …”
  9. 36189
  10. 36190
  11. 36191
  12. 36192
  13. 36193
  14. 36194
  15. 36195
  16. 36196
  17. 36197
  18. 36198
  19. 36199
  20. 36200